Pfizer Inc. $PFE Stake Lessened by TFB Advisors LLC

TFB Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 26.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,629 shares of the biopharmaceutical company’s stock after selling 4,178 shares during the period. TFB Advisors LLC’s holdings in Pfizer were worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Pacer Advisors Inc. raised its holdings in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Nuveen LLC acquired a new position in Pfizer during the first quarter worth $389,861,000. Starboard Value LP acquired a new position in Pfizer during the fourth quarter worth $407,730,000. Goldman Sachs Group Inc. increased its position in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after buying an additional 7,581,030 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.2%

PFE stock opened at $25.3750 on Thursday. The company has a market cap of $144.27 billion, a PE ratio of 13.50, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The business’s 50-day simple moving average is $24.66 and its 200 day simple moving average is $24.42.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. HSBC lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wolfe Research raised their price target on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Finally, UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.